Abstract: Over the past 40 years, the frequency of the DRM M184V (50-64.3%, p=0.363), G190A (17.2-46.2%, p=0.021), and K103N (34.5-42.3%, p=0.551) increased, while the frequency of Y181C (17.2-7.7%, p=0.289) decreased.
Abstract: The major DRM in the NRTIs was the M184V, whereas the G190A, K103N, and Y181C were the major DRMs in the NNRTIs.
High Prevalence of HIV-1 Drug Resistance and Dynamics of Transmission Among High-Risk Populations in Port-au-Prince, Haiti.
PMID: 33136738
2020
Journal of acquired immune deficiency syndromes (1999)
Abstract: Five clusters (62.5%) had shared DRMs, and K103N and M184V were the main shared mutations.
Result: Five clusters had shared resistance mutations, and K103N (14/24) and M184V (12/24) were the main DRM shared.
Result: Of the DRM, K103N (46/119; 38.6%), which causes high-level resistance to efavirenz and nevirapine, and M184V (35/119; 29.4%), associated with TDF and Emtricitabine (FTC) resistance, were the most frequently observed.
Predictors of first-line antiretroviral therapy failure among adults and adolescents living with HIV/AIDS in a large prevention and treatment program in Nigeria.
Abstract: Of 198 patient-derived samples sequenced during virologic failure, 42 (21%) were wild-type; 145 (73%) carried NNRTI drug resistance mutations; 151 (76.3%) M184I/V; 29 (14.6%) had >= 3 TAMs, and 37 (18.7%) had K65R, of whom all were on TDF-containing first-line regimens.
In Vivo Emergence of a Novel Protease Inhibitor Resistance Signature in HIV-1 Matrix.
Result: These mutations were observed at increased frequency at VF2 both by target-enriched NGS and also direct gag-pro PCR from plasma, but NGS also showed emergence of the lamivudine resistance mutation M184V, suggesting improved adherence to the lamivudine regimen between VF1 and VF2.
Table: M184V
Kinetics of Archived M184V Mutation in Treatment-Experienced Virally Suppressed HIV-Infected Patients.
Abstract: In addition, this case highlights the need for viral load monitoring in patients on dolutegravir-containing regimens in settings with a high prevalence of the M184V/I mutation such as in low-income countries.
Abstract: This case illustrates that dolutegravir-containing triple-therapy should be prescribed with caution to patients with pre-existing M184V/I mutation and poor efficacy of the reverse transcriptase inhibitor backbone.
Abstract: We describe a rare case of a patient with pre-existing M184V/I mutation and virological failure on a dolutegravir/lamivudine/abacavir regimen with the emergence of integrase strand transfer inhibitor resistance mutations.
Conclusion: In conclusion, we describe a rare case of a virological failure on the DTG/3TC/ABC regimen with the emergen
Genotyping and antiretroviral drug resistance of human immunodeficiency Virus-1 in Jazan, Saudi Arabia.
Result: Five patients had the same resistance mutations to NRTI (M184 V), these patients had different genotypes (B, C, and G), and this mutation is associated with resistance to the antiretroviral drugs: Lamivudine (3TC), Abacavir (ABC), and Emtricitabine (FTC).
Result: One patient had multi-drug mutation; the mutations (V82A + I84IV) and (L10F + Q58E) were found in the protease region while mutation M184 V was found to confer resistance to NRTI drugs.
Result: One patient had multiple resistance mutations to PI (V82A + I84IV,
Prevalence of HIV-1 Integrase Strand Transfer Inhibitor Resistance in Treatment-Naive Voluntary Counselling and Testing Clients by Population Sequencing and Illumina Next-Generation Sequencing in Taiwan.
Result: The most common RAMs to NRTIs were M184V and K65R (1.3%), while those for NNRTIs were V179D (4.5%), V106I (2.7%), and K103N (1.3%), and those for Figure: The figure shows that the most common drug resistance-associated mutations were M184V (1.3%) and K65R (1.3%) for NRTIs, V179D (4.5%), V106I (2.7%) and K103N (1.3%) for NNRTIs, and L10I (13.4%) and A71T (5.8%) for PIs.
Prevalence of human immunodeficiency virus-1 drug-resistant mutations among adults on first- and second-line antiretroviral therapy in a resource-limited health facility in Busia County, Kenya.
PMID: 33654530
2020
The Pan African medical journal
Introduction: A study on HIV-1 drug-resistance patterns in Nairobi identified M184V, K65R, T215Y and K70R mutations conferring resistance to NRTIs and K103N, G190A, V106A, Y184V, A98G, Y181C mutations conferring resistance to NNRTIs.
Result: Predominant NNRTIs mutations were K103N, Y181C, G190A, H221Y, and K101E; NRTIs
[Prevalence of transmitted drug resistance in HIV-infected treatment-naive patients in Chile].
Abstract: The mutations in reverse transcriptase were M41L, L210W, D67N, K70E, M184V, K103N (6.36%, 95% CI 3.5-10.4), G190A, E138A, K101E, and I84V in protease.
Use of a mutation-specific genotyping method to assess for HIV-1 drug resistance in antiretroviral-naive HIV-1 Subtype C-infected patients in Botswana.
Discussion: Another limitation in this study was the lack of samples with M184V and V106M, making it difficult to draw a conclusion on the performance of PANDAA in detecting V106M and M184V.
Discussion: By using PANDAA, we targeted the most likely mutations to develop to these medications in HIV-1 subtype C, the M184V, K103N and V106M mutations in reverse transcriptase, a targeted and cost-effective approach to genotyping is possible .
Discussion: Firstly, we only examined the most common relevant resistant mutations, V106M, K103N and M184V of the reverse transcriptase<
HIV mutation literature information.
PMID: 
2020
AIDS reviews
Browser Board
Co-occurred Entities
Filtrator
ViMRT